APA (7th ed.) Citation

Jilg, S., Schwaab, J., Sockel, K., Crodel, C. C., Brueckl, V., Stegelmann, F., . . . Petrides, P. E. (2024). MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of hematology, 103(10), . https://doi.org/10.1007/s00277-024-05908-4

Chicago Style (17th ed.) Citation

Jilg, Stefanie, et al. "MoReLife - Real-life Data Support the Potential of Momelotinib as a Safe and Effective Treatment Option for Cytopenic Myelofibrosis Patients." Annals of Hematology 103, no. 10 (2024). https://doi.org/10.1007/s00277-024-05908-4.

MLA (9th ed.) Citation

Jilg, Stefanie, et al. "MoReLife - Real-life Data Support the Potential of Momelotinib as a Safe and Effective Treatment Option for Cytopenic Myelofibrosis Patients." Annals of Hematology, vol. 103, no. 10, 2024, https://doi.org/10.1007/s00277-024-05908-4.